Literature DB >> 33730246

[Neuromonitoring of the cochlear nerve during vestibular schwannoma resection and simultaneous cochlear implantation. German version].

Nora M Weiss1, Wilma Großmann2, Sebastian Schraven2, Tobias Oberhoffner2, Robert Mlynski2.   

Abstract

Vestibular schwannomas (VS) are benign tumors that originate from the nerve sheath of one of the two vestibular nerves. VS can have a severe impact on everyday life of the patient and may lead to symptoms such as vertigo, hearing loss (e.g., as sudden deafness), deafness, and tinnitus. Treatment concepts include observational waiting with regular imaging control ("wait and scan"), radiotherapy, or surgical resection. Depending on the size of the tumor and status of functional hearing, the surgical approach may be retrosigmoidal, transtemporal, retrolabyrinthine, or translabyrinthine. The translabyrinthine approach always results in complete deafness due to opening of the bony labyrinth. If the nerve structure of the cochlear nerve is preserved, hearing rehabilitation with a cochlear implant (CI) may be successful. In this article the surgical technique for microsurgical resection of VS using a translabyrinthine approach with simultaneous cochlear implantation under intraoperative monitoring of the cochlear nerve by electrical stimulation is presented.

Entities:  

Keywords:  Acoustic neuroma; Audiologic rehabilitation; Cochlear implants; Hearing loss; Tinnitus

Year:  2021        PMID: 33730246     DOI: 10.1007/s00106-021-00996-4

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  40 in total

1.  Outcome on hearing and facial nerve function in microsurgical treatment of small vestibular schwannoma via the middle cranial fossa approach.

Authors:  Christian Ginzkey; Matthias Scheich; Wilma Harnisch; Verena Bonn; Desiree Ehrmann-Müller; Wafaa Shehata-Dieler; Robert Mlynski; Rudolf Hagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-22       Impact factor: 2.503

2.  [Management of vestibular schwannomas].

Authors:  Cordelia Schulz; Dirk Eßer; Steffen Rosahl; Izet Baljić; Sabrina Kösling; Stefan K Plontke
Journal:  Laryngorhinootologie       Date:  2018-12-10       Impact factor: 1.057

Review 3.  The cerebellopontine angle.

Authors:  A N Hasso; D S Smith
Journal:  Semin Ultrasound CT MR       Date:  1989-06       Impact factor: 1.875

4.  Hearing loss and growth rate of acoustic neuromas in follow-up observation policy.

Authors:  T Sakamoto; S Fukuda; Y Inuyama
Journal:  Auris Nasus Larynx       Date:  2001-05       Impact factor: 1.863

Review 5.  Acoustic neuroma growth: a systematic review of the evidence.

Authors:  Thomas P Nikolopoulos; Heather Fortnum; Gerard O'Donoghue; David Baguley
Journal:  Otol Neurotol       Date:  2010-04       Impact factor: 2.311

6.  What is the site of origin of cochleovestibular schwannomas?

Authors:  Christof Roosli; Fred H Linthicum; Sebahattin Cureoglu; Saumil N Merchant
Journal:  Audiol Neurootol       Date:  2011-09-29       Impact factor: 1.854

7.  Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.

Authors:  Victor-Felix Mautner; Rosa Nguyen; Hannes Kutta; Carsten Fuensterer; Carsten Bokemeyer; Christian Hagel; Reinhard E Friedrich; Jens Panse
Journal:  Neuro Oncol       Date:  2009-10-20       Impact factor: 12.300

Review 8.  Epidemiology and natural history of vestibular schwannomas.

Authors:  Sven-Eric Stangerup; Per Caye-Thomasen
Journal:  Otolaryngol Clin North Am       Date:  2012-02-28       Impact factor: 3.346

Review 9.  Growth rate of vestibular schwannoma.

Authors:  Iddo Paldor; Annie S Chen; Andrew H Kaye
Journal:  J Clin Neurosci       Date:  2016-07-20       Impact factor: 1.961

10.  Epidemiology Of Vestibular Schwannomas - Prospective 40-Year Data From An Unselected National Cohort.

Authors:  Martin Reznitsky; Mette Marie Babiel Schmidt Petersen; Niels West; Sven-Eric Stangerup; Per Cayé-Thomasen
Journal:  Clin Epidemiol       Date:  2019-11-08       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.